Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed renal cell carcinoma~  * Metastatic disease OR unresectable primary tumor~ * No known curative therapy exists~* Documented progressive renal cell carcinoma as defined by RECIST criteria within the past 6 months~* Measurable disease with ≥ 1 unidimensionally measurable lesion~* No known symptomatic brain metastasis or untreated brain metastases or carcinomatous meningitis~  * Treated brain metastasis allowed provided the following criteria are met:~    * Clinically stable~   * More than 7 days since prior steroids~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Life expectancy ≥ 3 months~* Absolute neutrophil count ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Bilirubin ≤ 1.5 times upper limit of normal (ULN)~* AST and ALT ≤ 2.5 times ULN~* Creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 60 mL/min~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective nonhormonal contraception during and for 3 months after completion of study treatment~* Must be able to swallow oral medication~* No coexisting medical condition that would preclude study compliance~* No history of allergic reaction to compounds of similar chemical or biological composition to gemcitabine hydrochloride and/or imatinib mesylate~* No uncontrolled illness that would preclude study participation~* No symptomatic congestive heart failure~* No unstable angina pectoris~* No cardiac arrhythmia requiring therapy~* No myocardial infarction within the past 6 months~* No active infection~* No other malignancy within the past 5 years except carcinoma in situ of the cervix or nonmelanoma skin cancer~* No New York Heart Association class III-IV congestive heart failure~* No known chronic liver disease (i.e., chronic active hepatitis or cirrhosis)~* No known HIV positivity~* No significant history of noncompliance to medical regimens~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Recovered from all prior therapy~* No more than 3 prior treatment regimens, including any of the following:~  * No more than 1 prior cytotoxic therapy~ * Immunotherapy regimens comprising interferon and/or aldesleukin~ * Therapy with molecular targets~ * Any combination of the above treatments to a maximum of 3 total therapies~* No prior gemcitabine hydrochloride for metastatic disease~* No prior imatinib mesylate for metastatic disease~* More than 2 weeks since prior major surgery~* At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas)~* At least 3 weeks since prior anti-vascular endothelial growth factor therapy~* At least 3 weeks since prior radiotherapy~  * Must have evidence of ≥ 1 measurable target lesion outside the radiation fields OR radiologically confirmed disease progression within the radiation fields after completion of radiotherapy~* At least 28 days since prior and no other concurrent investigational or commercial agents, unless disease is rapidly progressing~* No concurrent therapeutic warfarin~  * Concurrent low molecular weight heparin or heparin allowed for therapeutic anticoagulation~ * Concurrent prophylactic warfarin therapy ≤ 1 mg daily to maintain catheter patency allowed~* No concurrent filgrastim (G-CSF) for prevention of neutropenia~* No other concurrent chemotherapy, immunotherapy, hormonal cancer therapy, radiation therapy, or cancer surgery~* No concurrent routine use (i.e., daily or every other day) of systemic corticosteroid therapy (in supraphysiologic doses)~* No concurrent medication that would preclude study compliance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).